

# Patricia T Illing

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4248752/publications.pdf>

Version: 2024-02-01

39  
papers

2,186  
citations

331259

21  
h-index

344852

36  
g-index

40  
all docs

40  
docs citations

40  
times ranked

3285  
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial: The Immunology of Adverse Drug Reactions. <i>Frontiers in Immunology</i> , 2022, 13, 863414.	2.2	0
2	HLA-A*11:01-restricted CD8+ T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people. <i>PLoS Pathogens</i> , 2022, 18, e1010337.	2.1	11
3	T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
4	New insights and approaches for analyses of immunopeptidomes. <i>Current Opinion in Immunology</i> , 2022, 77, 102216.	2.4	3
5	The complexity of T cell-mediated penicillin hypersensitivity reactions. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 150-167.	2.7	11
6	Anthem: a user customised tool for fast and accurate prediction of binding between peptides and HLA class I molecules. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	37
7	Carbamazepine Induces Focused T Cell Responses in Resolved Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Cases But Does Not Perturb the Immunopeptidome for T Cell Recognition. <i>Frontiers in Immunology</i> , 2021, 12, 653710.	2.2	14
8	Resourcing, annotating, and analysing synthetic peptides of SARS-CoV-2 for immunopeptidomics and other immunological studies. <i>Proteomics</i> , 2021, 21, e2100036.	1.3	7
9	CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph. <i>Nature Communications</i> , 2021, 12, 2931.	5.8	20
10	Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire. <i>Frontiers in Immunology</i> , 2021, 12, 672737.	2.2	8
11	ggVolcanoR: A Shiny app for customizable visualization of differential expression datasets. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 5735-5740.	1.9	19
12	A natural product compound inhibits coronaviral replication in vitro by binding to the conserved Nsp9 SARS-CoV-2 protein. <i>Journal of Biological Chemistry</i> , 2021, 297, 101362.	1.6	35
13	Modification of the cyclopropyl moiety of abacavir provides insight into the structure activity relationship between HLA-B*57:01 binding and T cell activation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 636-647.	2.7	19
14	Identification of Flucloxacillin-Haptenated HLA-B*57:01 Ligands: Evidence of Antigen Processing and Presentation. <i>Toxicological Sciences</i> , 2020, 177, 454-465.	1.4	21
15	Thermostability profiling of MHC-bound peptides: a new dimension in immunopeptidomics and aid for immunotherapy design. <i>Nature Communications</i> , 2020, 11, 6305.	5.8	14
16	Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 1236-1247.	2.5	25
17	The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 11636-11647.	3.3	16
18	Response to Comment on "A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands". <i>Science Immunology</i> , 2019, 4, .	5.6	25

#	ARTICLE	IF	CITATIONS
19	Downregulation of MHC Class I Expression by Influenza A and B Viruses. <i>Frontiers in Immunology</i> , 2019, 10, 1158.	2.2	65
20	HLA-associated antiepileptic drug-induced cutaneous adverse reactions. <i>Hla</i> , 2019, 93, 417-435.	0.4	52
21	Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. <i>Nature Immunology</i> , 2019, 20, 613-625.	7.0	180
22	Identification of Native and Posttranslationally Modified HLA-B*57:01-Restricted HIV Envelope Derived Epitopes Using Immunoproteomics. <i>Proteomics</i> , 2018, 18, e1700253.	1.3	23
23	HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome. <i>Nature Communications</i> , 2018, 9, 4693.	5.8	31
24	A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands. <i>Science Immunology</i> , 2018, 3, .	5.6	142
25	Employing proteomics in the study of antigen presentation: an update. <i>Expert Review of Proteomics</i> , 2018, 15, 637-645.	1.3	23
26	MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 387-394.	3.6	83
27	The molecular basis for peptide repertoire selection in the human leukocyte antigen (HLA) C*06:02 molecule. <i>Journal of Biological Chemistry</i> , 2017, 292, 17203-17215.	1.6	34
28	The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. <i>Immunogenetics</i> , 2017, 69, 617-630.	1.2	63
29	Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions. <i>Current Opinion in Immunology</i> , 2016, 42, 31-40.	2.4	47
30	HLA and Drug Hypersensitivity. , 2016, , 310-317.		0
31	A comprehensive analysis of peptides presented by HLA-A1. <i>Tissue Antigens</i> , 2015, 85, 492-496.	1.0	27
32	The Cellular Redox Environment Alters Antigen Presentation. <i>Journal of Biological Chemistry</i> , 2014, 289, 27979-27991.	1.6	52
33	Using mass spectrometry to monitor drug induced changes in antigen presentation by the human leukocyte antigen. <i>Clinical and Translational Allergy</i> , 2014, 4, P43.	1.4	0
34	Human leukocyte antigen-associated drug hypersensitivity. <i>Current Opinion in Immunology</i> , 2013, 25, 81-89.	2.4	76
35	Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. <i>Journal of Experimental Medicine</i> , 2012, 209, 761-774.	4.2	159
36	Constitutive and Inflammatory Immunopeptidome of Pancreatic $\beta$ -Cells. <i>Diabetes</i> , 2012, 61, 3018-3025.	0.3	67

#	ARTICLE	IF	CITATIONS
37	Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. <i>Nature</i> , 2012, 486, 554-558.	13.7	612
38	Drug Hypersensitivity and Human Leukocyte Antigens of the Major Histocompatibility Complex. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 401-431.	4.2	146
39	Personalized medicine for HLA-associated drug-hypersensitivity reactions. <i>Personalized Medicine</i> , 2010, 7, 495-516.	0.8	15